# Reflect Scientific, Inc.: overview RSCF · OTC · CIK 1103090 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rscf.md) · [Financials](/companies/rscf/financials.md) · [Filings](/companies/rscf/filings.md) · [Insiders](/companies/rscf/insiders.md) Latest reported revenue: [$514.0k](/filings/0001548123-24-000126.md) for Q3 FY2024, three months to 2024-09-30, from the 10-Q filed Nov 12, 2024 (XBRL us-gaap:Revenues, accession 0001548123-24-000126). ## Last eight quarters | Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [479 d](/filings/0001548123-24-000032.md) | [241](/filings/0001548123-24-000073.md) | [124](/filings/0001548123-24-000101.md) | [526](/filings/0001548123-24-000126.md) | [189 d](/filings/0001548123-24-000032.md) | [429](/filings/0001548123-24-000073.md) | [590](/filings/0001548123-24-000101.md) | [514](/filings/0001548123-24-000126.md) | | Gross margin | % | [43.7% d](/filings/0001548123-24-000032.md) | [52.9%](/filings/0001548123-24-000073.md) | [48.7%](/filings/0001548123-24-000101.md) | [62.8%](/filings/0001548123-24-000126.md) | [41.5% d](/filings/0001548123-24-000032.md) | [56.4%](/filings/0001548123-24-000073.md) | [60.8%](/filings/0001548123-24-000101.md) | [63.8%](/filings/0001548123-24-000126.md) | | Operating margin | % | [(12.8%) d](/filings/0001548123-24-000032.md) | [(61.3%)](/filings/0001548123-24-000073.md) | [(145.3%)](/filings/0001548123-24-000101.md) | [15.4%](/filings/0001548123-24-000126.md) | [(116.3%) d](/filings/0001548123-24-000032.md) | [(9.4%)](/filings/0001548123-24-000073.md) | [16.7%](/filings/0001548123-24-000101.md) | [19.3%](/filings/0001548123-24-000126.md) | | Net margin | % | [(12.8%) d](/filings/0001548123-24-000032.md) | [(61.3%)](/filings/0001548123-24-000126.md) | [(145.6%)](/filings/0001548123-24-000126.md) | [16.4%](/filings/0001548123-24-000126.md) | [(114.6%) d](/filings/0001548123-24-000032.md) | [(7.5%)](/filings/0001548123-24-000126.md) | [18.5%](/filings/0001548123-24-000126.md) | [21.4%](/filings/0001548123-24-000126.md) | | Diluted EPS | $ per share | not reported | [0.00](/filings/0001548123-24-000073.md) | [0.00](/filings/0001548123-24-000101.md) | [0.00](/filings/0001548123-24-000126.md) | not reported | [0.00](/filings/0001548123-24-000073.md) | [0.00](/filings/0001548123-24-000101.md) | [0.00](/filings/0001548123-24-000126.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2019 (2019-12-31) | FY (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,609](/filings/0001548123-20-000035.md) | [2,793](/filings/0001548123-22-000034.md) | [2,815](/filings/0001548123-23-000056.md) | [2,041](/filings/0001548123-24-000032.md) | [1,080](/filings/0001548123-24-000032.md) | | Gross margin | % | [61.6%](/filings/0001548123-20-000035.md) | [61.6%](/filings/0001548123-22-000034.md) | [68.6%](/filings/0001548123-23-000056.md) | [59.7%](/filings/0001548123-24-000032.md) | [55.2%](/filings/0001548123-24-000032.md) | | Operating margin | % | [(12.1%)](/filings/0001548123-20-000035.md) | [23.3%](/filings/0001548123-22-000034.md) | [29.4%](/filings/0001548123-23-000056.md) | [4.4%](/filings/0001548123-24-000032.md) | [(43.3%)](/filings/0001548123-24-000032.md) | | Net margin | % | [(12.2%)](/filings/0001548123-20-000035.md) | [23.6%](/filings/0001548123-22-000034.md) | [33.4%](/filings/0001548123-23-000056.md) | [4.4%](/filings/0001548123-24-000032.md) | [(42.5%)](/filings/0001548123-24-000032.md) | | Diluted EPS | $ per share | [0.00](/filings/0001548123-20-000035.md) | [0.01](/filings/0001548123-22-000034.md) | [0.01](/filings/0001548123-23-000056.md) | [0.00](/filings/0001548123-24-000032.md) | [(0.01)](/filings/0001548123-24-000032.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rscf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RMG Wealth Management LLC](/funds/1844731.md) | 2026-06-30 | $57 | 1,300 | | New +1,300 | ## Recent filings [All 138 filings](/companies/rscf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2024-11-12 | 15:46 ET | [10-Q](/filings/0001548123-24-000126.md) | Quarterly report, period 2024-09-30 | 0001548123-24-000126 | | 2024-08-13 | 13:13 ET | [10-Q](/filings/0001548123-24-000101.md) | Quarterly report, period 2024-06-30 | 0001548123-24-000101 | | 2024-05-13 | 14:53 ET | [10-Q](/filings/0001548123-24-000073.md) | Quarterly report, period 2024-03-31 | 0001548123-24-000073 | | 2024-03-29 | 15:20 ET | [10-K](/filings/0001548123-24-000032.md) | Annual report, period 2023-12-31 | 0001548123-24-000032 | | 2023-11-09 | 14:22 ET | [10-Q](/filings/0001548123-23-000167.md) | Quarterly report, period 2023-09-30 | 0001548123-23-000167 | | 2023-08-08 | 11:22 ET | [10-Q](/filings/0001548123-23-000137.md) | Quarterly report, period 2023-06-30 | 0001548123-23-000137 | | 2023-05-11 | 15:24 ET | [10-Q](/filings/0001548123-23-000102.md) | Quarterly report, period 2023-03-31 | 0001548123-23-000102 | | 2023-03-31 | 18:53 ET | [10-K](/filings/0001548123-23-000056.md) | Annual report, period 2022-12-31 | 0001548123-23-000056 | | 2022-11-09 | 15:56 ET | [10-Q](/filings/0001548123-22-000178.md) | Quarterly report, period 2022-09-30 | 0001548123-22-000178 | | 2022-08-10 | 13:20 ET | [10-Q](/filings/0001548123-22-000114.md) | Quarterly report, period 2022-06-30 | 0001548123-22-000114 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2023](/filings/0001548123-24-000032.md), filed Mar 29, 2024. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1103090 - Tickers: RSCF - Exchange: OTC - SIC code: 3821 Laboratory Apparatus & Furniture - State of incorporation: UT - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.